These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31978505)

  • 1. Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue.
    Deftereos G; Sandoval A; Furtado LV; Bronner M; Matynia AP
    Hum Pathol; 2020 Mar; 97():52-59. PubMed ID: 31978505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry Profile Predicts
    Li W; Niehaus AG; O'Neill SS
    Int J Surg Pathol; 2020 Aug; 28(5):502-506. PubMed ID: 32114861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
    Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample features associated with success rates in population-based EGFR mutation testing.
    Shiau CJ; Babwah JP; da Cunha Santos G; Sykes JR; Boerner SL; Geddie WR; Leighl NB; Wei C; Kamel-Reid S; Hwang DM; Tsao MS
    J Thorac Oncol; 2014 Jul; 9(7):947-956. PubMed ID: 24922009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
    Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
    Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.
    Thunnissen E; Boers E; Heideman DA; Grünberg K; Kuik DJ; Noorduin A; van Oosterhout M; Pronk D; Seldenrijk C; Sietsma H; Smit EF; van Suylen R; von der Thusen J; Vrugt B; Wiersma A; Witte BI; den Bakker M
    Virchows Arch; 2012 Dec; 461(6):629-38. PubMed ID: 23064619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
    Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
    Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
    Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
    Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
    Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
    Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas.
    Shanzhi W; Yiping H; Ling H; Jianming Z; Qiang L
    PLoS One; 2014; 9(4):e95479. PubMed ID: 24743427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
    Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
    Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
    Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
    Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
    Kanmaz ZD; Aras G; Tuncay E; Bahadır A; Kocatürk C; Yaşar ZA; Öz B; Özkurt CÜ; Gündoğan C; Çermik TF
    Cancer Biomark; 2016; 16(3):489-98. PubMed ID: 27062706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation testing in pulmonary adenocarcinoma: evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies.
    Scarpino S; Pulcini F; Di Napoli A; Giubettini M; Ruco L
    Lung Cancer; 2015 Jan; 87(1):8-13. PubMed ID: 25468201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.